08 Jun Treating Metastatic Cervical Cancer With HPV-Targeted TILs

MedicalResearch.com Interview with:
Dr. Christian S Hinrichs MD
Assistant Clinical Investigator
Center for Cancer Research
National Cancer Institute
Bethesda, MD 20814

MedicalResearch: What are the main findings of the study?

Dr. Hinrichs: Objective tumor regression occurred in 3/9 patients with metastatic cervical cancer. Two responses were complete and are ongoing 22 and 15 months after treatment with a single infusion of T cells targeting the HPV oncoproteins.

MedicalResearch: Were any of the findings unexpected?

Dr. Hinrichs:  The findings were unexpected in that durable, complete responses of metastatic cervical cancer to any treatment is unusual.

MedicalResearch: What should clinicians and patients take away from your report?

Dr. Hinrichs:  There is a clinical trial for metastatic cervical cancer open at the NIH Clinical Center, and it has shown promising early results, but further study is needed.

MedicalResearch: What recommendations do you have for future research as a result of this study?

Dr. Hinrichs:  We are continuing this study to better define the response rate to the treatment. We are also studying the same approach in non-cervical HPV+ cancers such as oropharyngeal and anal malignancies.

Citation:

Abstract presented at the 2014 ASCO Meeting

HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.

Christian S. Hinrichs, Sanja Stevanovic, Lindsey Draper, Robert Somerville, John Wunderlich, Nicholas P. Restifo, Richard Sherry, Phan Q Giao, Udai S. Kammula, James C. Yang, Steven A. Rosenberg; National Cancer Institute, Bethesda, MD; Surgery Branch, National Cancer Institute, Bethesda, MD

Abstract No: LBA3008

Last Updated on December 21, 2014 by Marie Benz MD FAAD